U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
Colistimethate is a methanesulfonate of polymyxin antibacterial colistin. Colistimethate is a nonactive prodrug. In aqueous solutions, colistimethate is hydrolyzed and forms a complex mixture of partially sulfomethylated derivatives and colistin. The antimicrobial activity of colistin is similar to that of polymyxin B and is restricted to gram-negative bacteria, including P aeruginosa, Acinetobacter species, Enterobacter-Klebsiella tribe, Escherichia coli, Salmonella and Shigella species, Citrobacter species, Yersinia pseudotuberculosis, Morganella morganii and Haemophilus influenzae. Colistin has also been shown to possess considerable in vitro activity against Stenotrophomonas maltophilia. Colistin and polymyxin B, however, do not have activity against Proteus, Providencia, Serratia species, Pseudomonas mallei, Burkholderia cepacia, Brucella species, most gram-positive bacteria, gram-negative cocci, anaerobes, fungi and parasites. Parenteral or nebulized colistimethate is indicated for the treatment of acute or chronic infections due to sensitive strains of certain gram-negative bacilli. It is particularly indicated when the infection is caused by sensitive strains of Pseudomonas aeruginosa.

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Curative
COLY-MYCIN M

Approved Use

Colistimethate for injection is indicated for the treatment of acute or chronic infections due to sensitive strains of certain gram-negative bacilli. It is particularly indicated when the infection is caused by sensitive strains of Pseudomonas aeruginosa. This antibiotic is not indicated for infections due to Proteus or Neisseria. Colistimethate for injection has proven clinically effective in treatment of infections due to the following gram-negative organisms: Enterobacter aerogenes, Escherichia coli, Klebsiella pneumoniae and Pseudomonas aeruginosa. Colistimethate for injection may be used to initiate therapy in serious infections that are suspected to be due to gram-negative organisms and in the treatment of infections due to susceptible gram-negative pathogenic bacilli. To reduce the development of drug-resistant bacteria and maintain the effectiveness of colistimethate for injection and other antibacterial drugs, colistimethate for injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

Launch Date

1.33056E10
PubMed

PubMed

TitleDatePubMed
[Recovery after hemodialysis in 2 cases of acute renal insufficiency during treatment with kanamycin and colistin methanesulfonate].
1970 Apr 27

Sample Use Guides

Either 75 mg or 150 mg twice a day by nebulization. Parenteral should be given in 2 to 4 divided doses at dose levels of 2.5 to 5 mg/kg per day for patients with normal renal function, depending on the severity of the infection.
Route of Administration: Other
Substance Class Mixture
Created
by admin
on Fri Dec 15 15:57:57 UTC 2023
Edited
by admin
on Fri Dec 15 15:57:57 UTC 2023
Record UNII
DL2R53P963
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
COLISTIMETHATE
VANDF  
Common Name English
COLISTIN SULFOMETHATE
WHO-DD  
Common Name English
COLISTINMETHANESULFONIC ACID
Common Name English
COLISTIMETHATE [VANDF]
Common Name English
Colistin sulfomethate [WHO-DD]
Common Name English
COLISTIN METHANESULFONIC ACID
Common Name English
Classification Tree Code System Code
NDF-RT N0000007822
Created by admin on Fri Dec 15 15:57:57 UTC 2023 , Edited by admin on Fri Dec 15 15:57:57 UTC 2023
NDF-RT N0000175499
Created by admin on Fri Dec 15 15:57:57 UTC 2023 , Edited by admin on Fri Dec 15 15:57:57 UTC 2023
NDF-RT N0000007822
Created by admin on Fri Dec 15 15:57:57 UTC 2023 , Edited by admin on Fri Dec 15 15:57:57 UTC 2023
NDF-RT N0000007822
Created by admin on Fri Dec 15 15:57:57 UTC 2023 , Edited by admin on Fri Dec 15 15:57:57 UTC 2023
NDF-RT N0000007822
Created by admin on Fri Dec 15 15:57:57 UTC 2023 , Edited by admin on Fri Dec 15 15:57:57 UTC 2023
NCI_THESAURUS C52588
Created by admin on Fri Dec 15 15:57:57 UTC 2023 , Edited by admin on Fri Dec 15 15:57:57 UTC 2023
NDF-RT N0000007822
Created by admin on Fri Dec 15 15:57:57 UTC 2023 , Edited by admin on Fri Dec 15 15:57:57 UTC 2023
CFR 21 CFR 556.167
Created by admin on Fri Dec 15 15:57:57 UTC 2023 , Edited by admin on Fri Dec 15 15:57:57 UTC 2023
NDF-RT N0000007822
Created by admin on Fri Dec 15 15:57:57 UTC 2023 , Edited by admin on Fri Dec 15 15:57:57 UTC 2023
Code System Code Type Description
NCI_THESAURUS
C72729
Created by admin on Fri Dec 15 15:57:57 UTC 2023 , Edited by admin on Fri Dec 15 15:57:57 UTC 2023
PRIMARY
FDA UNII
DL2R53P963
Created by admin on Fri Dec 15 15:57:57 UTC 2023 , Edited by admin on Fri Dec 15 15:57:57 UTC 2023
PRIMARY
MESH
C004691
Created by admin on Fri Dec 15 15:57:57 UTC 2023 , Edited by admin on Fri Dec 15 15:57:57 UTC 2023
PRIMARY
EVMPD
SUB23213
Created by admin on Fri Dec 15 15:57:57 UTC 2023 , Edited by admin on Fri Dec 15 15:57:57 UTC 2023
PRIMARY
CAS
12705-41-8
Created by admin on Fri Dec 15 15:57:57 UTC 2023 , Edited by admin on Fri Dec 15 15:57:57 UTC 2023
PRIMARY
DAILYMED
DL2R53P963
Created by admin on Fri Dec 15 15:57:57 UTC 2023 , Edited by admin on Fri Dec 15 15:57:57 UTC 2023
PRIMARY
RXCUI
2708
Created by admin on Fri Dec 15 15:57:57 UTC 2023 , Edited by admin on Fri Dec 15 15:57:57 UTC 2023
PRIMARY RxNorm
DRUG BANK
DB01111
Created by admin on Fri Dec 15 15:57:57 UTC 2023 , Edited by admin on Fri Dec 15 15:57:57 UTC 2023
PRIMARY
LACTMED
Colistimethate
Created by admin on Fri Dec 15 15:57:57 UTC 2023 , Edited by admin on Fri Dec 15 15:57:57 UTC 2023
PRIMARY
CHEBI
34650
Created by admin on Fri Dec 15 15:57:57 UTC 2023 , Edited by admin on Fri Dec 15 15:57:57 UTC 2023
PRIMARY
Definition References